Weekly Vitamin D in Pediatric IBD

Emory University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Inflammatory Bowel Diseases; Skin Pigmentation

Treatments: Dietary Supplement: Vitamin D3 (cholecalciferol)

Study type: Interventional

Funder types: Other

Identifiers

NCT02076750

IRB00061627

Details and patient eligibility

About

The purpose of this study is to determine whether weekly dosing of oral vitamin D3 is effective in correcting low vitamin D levels in children and adolescents with inflammatory bowel disease (also known as Crohn's disease and ulcerative colitis).

Full description

The role of vitamin D in skeletal health is well established. More recently, vitamin D has been implicated in multiple other disease states and is currently a topic of much discussion in the pediatric and adult medical literature. Individuals with gastrointestinal or hepatobiliary diseases that limit the absorption of dietary vitamin D and those individuals with limited sunlight exposure or darker skin color are at risk for suboptimal vitamin D status. Recent joint guidelines from the North American and European Societies of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN and ESPGHAN, respectively) have recommended routine surveillance and treatment for vitamin D insufficiency/deficiency in children affected by inflammatory bowel diseases (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC). Current recommendations are for prolonged daily dosing of oral vitamin D, but studies in children with other chronic diseases have demonstrated the benefit of improved compliance with less frequent, higher doses of vitamin D. The primary goal of this pilot study is to establish whether weekly dosing of vitamin D can correct suboptimal vitamin D status in children with inflammatory bowel disease. A secondary goal is to evaluate whether pediatric IBD patients with darker skin respond differently to vitamin D therapy than do their lighter-skinned counterparts.

Enrollment: 34 patients

Sex: All

Ages: 8 to 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Established diagnosis of inflammatory bowel disease made by a pediatric gastroenterologist and confirmed by histopathology
2. Serum 25-OH vitamin D level <30 ng/mL at time of enrollment.
3. Age 8-21 years
4. Weight > 20 kg
5. Parent, guardian, or subject (where applicable) able to give consent/assent

Exclusion criteria

1. Inability to ingest oral vitamin D3 capsules
2. Presence of known hepatobiliary disease
3. Presence of known kidney disease or history of renal stones
4. Use of systemic steroids within 60 days prior to enrollment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

34 participants in 2 patient groups

Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight

Experimental group

Description:

Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.

Treatment:

Dietary Supplement: Vitamin D3 (cholecalciferol)

Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight

Active Comparator group

Description:

Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.

Treatment:

Dietary Supplement: Vitamin D3 (cholecalciferol)